Retrospective study links post-chemotherapy CBD/CBG exposure to fewer neuropathy-related diagnoses
A retrospective EHR study associated CBD/CBG exposure after chemotherapy with fewer neuropathy-related diagnosis codes versus active comparator medicines. Pre-chemotherapy exposure was not significant. Sparse events, exposure-record limitations and possible competing-risk bias make this exploratory, not proof of prevention or treatment.
For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.
Source
themarijuanaherald.com
CannabisInsight selects and summarizes news from external sources. Copyright in the original articles remains with the respective publishers or institutions. Follow the source links for full reporting and context.
Original Link
https://themarijuanaherald.com/2026/09/cbd-and-cbg-use-after-chemotherapy-linked-to-significantly-lower-neuropathy-risk-study-finds/